105 related articles for article (PubMed ID: 10661519)
1. Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration.
González AM; Berciano J; Figols J; Pazos A; Pascual J
Brain Res; 2000 Jan; 852(1):228-32. PubMed ID: 10661519
[TBL] [Abstract][Full Text] [Related]
2. Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1.
Kish SJ; Guttman M; Robitaille Y; el-Awar M; Chang LJ; Levey AI
Neurology; 1997 Apr; 48(4):1109-11. PubMed ID: 9109912
[TBL] [Abstract][Full Text] [Related]
3. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
Kaufman MJ; Madras BK
Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
[TBL] [Abstract][Full Text] [Related]
4. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
5. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
[TBL] [Abstract][Full Text] [Related]
6. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of cocaine: II. Mesocorticolimbic and striatal dopamine and cocaine receptors in C57BL and DBA mice.
Erwin VG; Womer DE; Campbell AD; Jones BC
Pharmacogenetics; 1993 Aug; 3(4):189-96. PubMed ID: 8220438
[TBL] [Abstract][Full Text] [Related]
8. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study.
Ułas J; Weihmuller FB; Brunner LC; Joyce JN; Marshall JF; Cotman CW
J Neurosci; 1994 Nov; 14(11 Pt 1):6317-24. PubMed ID: 7965038
[TBL] [Abstract][Full Text] [Related]
9. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
[TBL] [Abstract][Full Text] [Related]
11. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
Walker Z; Costa DC; Walker RW; Lee L; Livingston G; Jaros E; Perry R; McKeith I; Katona CL
Neurology; 2004 May; 62(9):1568-72. PubMed ID: 15136683
[TBL] [Abstract][Full Text] [Related]
12. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
Chinaglia G; Alvarez FJ; Probst A; Palacios JM
Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
[TBL] [Abstract][Full Text] [Related]
13. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
[TBL] [Abstract][Full Text] [Related]
14. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
Knudsen GM; Karlsborg M; Thomsen G; Krabbe K; Regeur L; Nygaard T; Videbaek C; Werdelin L
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
[TBL] [Abstract][Full Text] [Related]
15. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD.
Ichise M; Kim YJ; Ballinger JR; Vines D; Erami SS; Tanaka F; Lang AE
Neurology; 1999 Apr; 52(6):1206-14. PubMed ID: 10214745
[TBL] [Abstract][Full Text] [Related]
16. Striatal quinolinic acid lesions increase [3H]WIN 35,428 binding to the dopamine transporter.
Gehlert DR; Schoepp DD
Neurochem Int; 1992 Dec; 21(4):581-4. PubMed ID: 1303740
[TBL] [Abstract][Full Text] [Related]
17. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
Guttman M; Stewart D; Hussey D; Wilson A; Houle S; Kish S
Neurology; 2001 Jun; 56(11):1559-64. PubMed ID: 11402115
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease.
Ilgin N; Zubieta J; Reich SG; Dannals RF; Ravert HT; Frost JJ
Neurology; 1999 Apr; 52(6):1221-6. PubMed ID: 10214747
[TBL] [Abstract][Full Text] [Related]
19. Isothiocyanate derivatives of cocaine: irreversible inhibition of ligand binding at the dopamine transporter.
Boja JW; Rahman MA; Philip A; Lewin AH; Carroll FI; Kuhar MJ
Mol Pharmacol; 1991 Mar; 39(3):339-45. PubMed ID: 1826041
[TBL] [Abstract][Full Text] [Related]
20. Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy).
Puschban Z; Waldner R; Seppi K; Stefanova N; Humpel C; Scherfler C; Levivier M; Poewe W; Wenning GK
Exp Neurol; 2000 Jul; 164(1):166-75. PubMed ID: 10877927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
